PT-141
Melanocortin receptor agonist that enhances sexual function and desire
Clinical Research Score: 5/5 — FDA-approved as Vyleesi (bremelanotide) for hypoactive sexual desire disorder, backed by randomized Phase 3 trials.
Categories: Sexual Health
What is PT-141?
PT-141 is fundamentally different from every other option for sexual health — and that difference matters. Medications like Viagra and Cialis work on plumbing (blood flow). PT-141 works on desire. It acts directly in the brain, amplifying the signals that create genuine arousal and wanting.
People describe the effect as a noticeable increase in desire and sensitivity — not forced or mechanical, but a natural heightening of sexual interest. Colors seem brighter, touch feels more intense, and the mental component of arousal that often fades with age or stress comes back. Both men and women report benefits, which makes it unique in this space.
It's typically used as-needed rather than daily, making it practical for real-world use. The effects usually begin within an hour or two and can last for an extended window. For people who feel like the "spark" has dimmed — whether from stress, aging, or medication side effects — PT-141 addresses the root of desire rather than just the mechanics.
How PT-141 works
PT-141 activates melanocortin receptors (MC3R and MC4R) directly in the brain's arousal centers. Unlike blood-flow medications, it works on the central nervous system pathways that create sexual desire and arousal. It essentially turns up the volume on the brain's natural desire signals, which is why it works for both men and women and why the effect feels natural rather than forced.
Scientific overview
PT-141 (Bremelanotide) is a synthetic peptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It works through the melanocortin receptor system (MC3R and MC4R) in the central nervous system to enhance sexual arousal and desire. Unlike PDE5 inhibitors, PT-141 works on the brain rather than the vascular system, making it effective for both men and women with hypoactive sexual desire disorder.
Dosing
- Starting dose: 0.5 mg per dose
- Common dosage range: 1-2 mg per dose
- Administration: Subcutaneous, Nasal
- Half-life: ~4 hours
- Frequency: As needed, 1-2 hours before activity